Institutional investors purchased a net $7.3 million shares of HALO during the quarter ended March 2015. This may signal that the smart money is gaining interest in this company as the 66.47% of shares outstanding that institutional investors hold is actually below the Biotechnology industry average.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
IRIDIAN ASSET MANAGEMENT LLC Bought 4.9 Million shares of Halozyme Therapeutics Inc
CREATIVE PLANNING, INC. Bought 89.3 Thousand shares of Halozyme Therapeutics Inc